Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
relugolix
Biotech
Ex-Myovant chief Seely makes way for Amgen alum Marek
On the heels of its first approval, Myovant is tapping a new CEO to take that drug to market while stoking its R&D engine to find its successors.
Amirah Al Idrus
Jan 4, 2021 3:15pm
Myovant's relugolix falls short in metastatic prostate cancer
Sep 30, 2020 10:00am
Myovant details speedy effects of prostate cancer med relugolix
May 29, 2020 8:01am
